Immunitybio Inc (IBRX) — Strategic Asset Allocation Index
Immunitybio Inc (IBRX) has a Strategic Asset Allocation Index of 40.7% as of June 2020. Strategic assets (PP&E of $69.02 Million plus long-term investments of $-) total $69.02 Million, measured against net assets of $169.65 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Immunitybio Inc Strategic Asset Allocation Index (2016–2019)
This chart shows how Immunitybio Inc's Strategic Asset Allocation Index has evolved across 4 annual periods from 2016 to 2019. As of June 2020, the index stands at 40.7%, representing strategic assets of $69.02 Million against net assets of $169.65 Million USD. Explore Immunitybio Inc cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Immunitybio Inc (2016–2019)
The table below presents the year-by-year Strategic Asset Allocation Index for Immunitybio Inc from 2016 to 2019, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Immunitybio Inc (IBRX) total market value.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2019 | 23.0% | $27.78 Million | $27.78 Million | $- | $120.68 Million | ▲ +2.7 pp |
| 2018 | 20.3% | $29.63 Million | $29.63 Million | $- | $146.01 Million | ▼ -14.8 pp |
| 2017 | 35.1% | $76.73 Million | $76.73 Million | $- | $218.84 Million | ▲ +28.5 pp |
| 2016 | 6.6% | $19.38 Million | $19.38 Million | $- | $293.42 Million | — |